Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corvus PharmaceuticalsFRA:C17 -1.90%34 3-Year EBITDA Growth Rate is 8.00% as of Jun. 2026, which is 58% below its 10-year median of 19.15. GuruFocus rates FRA:C17 with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,127 Biotechnology companies, Corvus Pharmaceuticals ranks worse than 57.94% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 8.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 19.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 13.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Corvus Pharmaceuticals was 30.80% per year. The lowest was -38.10% per year. And the median was 19.15% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Corvus Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
FRA:C17 vs APMD, SANA, ODTX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Corvus Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corvus Pharmaceuticals 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Corvus Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 8.00% mean?
Corvus Pharmaceuticals (FRA:C17) has a 3-Year EBITDA Growth Rate of 8.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Corvus Pharmaceuticals and its competitors. This is 58% below median its historical median of 19.15. According to the industry distribution chart, Corvus Pharmaceuticals ranks #653 out of 1127 companies in the Biotechnology industry, placing it in the top 57.9%.
Is Corvus Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Corvus Pharmaceuticals' current 3-Year EBITDA Growth Rate of 8.00% is 58% below median its 10-year median of 19.15. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Corvus Pharmaceuticals' value of 8.00% is 45.2% below this industry median. Based on the distribution chart, Corvus Pharmaceuticals ranks #653 out of 1127 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Corvus Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Corvus Pharmaceuticals' 3-Year EBITDA Growth Rate compare to APMD and SANA?
According to the Biotechnology industry distribution chart, Corvus Pharmaceuticals ranks #653 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Corvus Pharmaceuticals in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. Corvus Pharmaceuticals' value of 8.00% is 45.2% below this benchmark. While the company's 10-year median is 19.15 vs. the industry median of 14.60, Corvus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corvus Pharmaceuticals's current 3-Year EBITDA Growth Rate of 8.00% is 45.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Corvus Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corvus Pharmaceuticals's current 3-Year EBITDA Growth Rate is 8.00%, which is 58% below median its own 10-year median of 19.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corvus Pharmaceuticals stock overvalued right now?
Corvus Pharmaceuticals (FRA:C17) has a current 3-Year EBITDA Growth Rate of 8.00%. The current 3-Year EBITDA Growth Rate is 8.00%, which is 58% below median its 10-year median of 19.15 and 45.2% below the Biotechnology industry median of 14.60. Corvus Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Corvus Pharmaceuticals (FRA:C17), the current 3-Year EBITDA Growth Rate is 8.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
34GF Score
Get the complete analysis for FRA:C17
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C17 has been successfully added to your 
